Patients with IBD treated with the original adalimumab reference product show a high acceptance of the switch to its ...

The results of an open-label extension study confirmed the interchangeability of biosimilar CT-917 with reference adalimumab for plaque psoriasis.

Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort ...

Celltrion, Inc. announced that the U.S. Food and Drug Administration granted an interchangeable designation to ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic inflammatory diseases, Celltrion USA announced in a press release.A high-concentration ...

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

Both Generics and Biosimilars segments underperformed, though the latter was notably weaker, missing consensus by 9%.

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Non-infectious uveitis is a rare immune-mediated condition in children and is often treated with the tumor necrosis factor inhibitor adalimumab. Discontinuing the drug may be considered when ...